Vestor Capital LLC Acquires 25 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Vestor Capital LLC boosted its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 10.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 256 shares of the pharmaceutical company’s stock after purchasing an additional 25 shares during the quarter. Vestor Capital LLC’s holdings in Vertex Pharmaceuticals were worth $104,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of VRTX. Venturi Wealth Management LLC boosted its holdings in Vertex Pharmaceuticals by 1.1% during the 4th quarter. Venturi Wealth Management LLC now owns 2,293 shares of the pharmaceutical company’s stock worth $933,000 after acquiring an additional 24 shares during the last quarter. Nicholas Hoffman & Company LLC. boosted its holdings in Vertex Pharmaceuticals by 3.9% during the fourth quarter. Nicholas Hoffman & Company LLC. now owns 636 shares of the pharmaceutical company’s stock worth $259,000 after purchasing an additional 24 shares during the last quarter. Arthur M. Cohen & Associates LLC grew its position in Vertex Pharmaceuticals by 3.2% in the 4th quarter. Arthur M. Cohen & Associates LLC now owns 800 shares of the pharmaceutical company’s stock worth $326,000 after purchasing an additional 25 shares in the last quarter. Baystate Wealth Management LLC increased its stake in Vertex Pharmaceuticals by 49.0% in the 4th quarter. Baystate Wealth Management LLC now owns 76 shares of the pharmaceutical company’s stock valued at $31,000 after buying an additional 25 shares during the last quarter. Finally, Arjuna Capital lifted its position in shares of Vertex Pharmaceuticals by 0.7% during the 3rd quarter. Arjuna Capital now owns 4,375 shares of the pharmaceutical company’s stock worth $1,521,000 after buying an additional 29 shares in the last quarter. 90.96% of the stock is currently owned by institutional investors and hedge funds.

Vertex Pharmaceuticals Stock Performance

VRTX traded up $0.17 on Thursday, reaching $418.99. The stock had a trading volume of 676,155 shares, compared to its average volume of 1,228,628. The company has a market cap of $108.29 billion, a P/E ratio of 30.16, a price-to-earnings-growth ratio of 1.89 and a beta of 0.39. Vertex Pharmaceuticals Incorporated has a 12-month low of $320.01 and a 12-month high of $448.40. The business’s 50-day moving average price is $407.86 and its two-hundred day moving average price is $400.88. The company has a current ratio of 3.99, a quick ratio of 3.78 and a debt-to-equity ratio of 0.02.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings data on Monday, May 6th. The pharmaceutical company reported $4.76 EPS for the quarter, beating analysts’ consensus estimates of $3.66 by $1.10. Vertex Pharmaceuticals had a net margin of 36.68% and a return on equity of 21.91%. The company had revenue of $2.69 billion during the quarter, compared to the consensus estimate of $2.58 billion. During the same quarter in the prior year, the firm earned $2.67 EPS. Vertex Pharmaceuticals’s quarterly revenue was up 13.3% on a year-over-year basis. Sell-side analysts forecast that Vertex Pharmaceuticals Incorporated will post 14.95 earnings per share for the current year.

Insider Activity

In other Vertex Pharmaceuticals news, EVP Ourania Tatsis sold 354 shares of the firm’s stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $425.70, for a total transaction of $150,697.80. Following the transaction, the executive vice president now owns 55,804 shares of the company’s stock, valued at $23,755,762.80. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In other Vertex Pharmaceuticals news, COO Stuart A. Arbuckle sold 4,295 shares of the business’s stock in a transaction on Monday, February 12th. The stock was sold at an average price of $420.24, for a total value of $1,804,930.80. Following the completion of the transaction, the chief operating officer now directly owns 75,718 shares in the company, valued at approximately $31,819,732.32. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Ourania Tatsis sold 354 shares of the firm’s stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $425.70, for a total value of $150,697.80. Following the completion of the transaction, the executive vice president now owns 55,804 shares in the company, valued at $23,755,762.80. The disclosure for this sale can be found here. In the last three months, insiders have sold 12,381 shares of company stock worth $5,203,249. 0.20% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on VRTX shares. Piper Sandler upped their target price on Vertex Pharmaceuticals from $450.00 to $456.00 and gave the company an “overweight” rating in a report on Tuesday. Needham & Company LLC reiterated a “hold” rating on shares of Vertex Pharmaceuticals in a research note on Tuesday. StockNews.com upgraded shares of Vertex Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, May 3rd. Truist Financial lifted their price objective on shares of Vertex Pharmaceuticals from $456.00 to $508.00 and gave the stock a “buy” rating in a research report on Wednesday, January 31st. Finally, Wolfe Research initiated coverage on shares of Vertex Pharmaceuticals in a research note on Thursday, February 15th. They issued an “outperform” rating and a $515.00 target price on the stock. Three investment analysts have rated the stock with a sell rating, seven have issued a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $432.18.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.